Guidelines for Primary, Secondary and Tertiary Level Care
This chapter discusses the antibacterial treatment of leprosy infections. Antibiotic treatment is
a key component of leprosy treatment, as it is vital to prevent the progression of the infection.
Treatment with rifampin and other antibiotics is highly effective and cures 98% of patients with
the ...leprosy infection. Furthermore, the relapse rate is very low, at about 1% over 5–10 years.
There is little M. leprae drug resistance in leprosy and few reports of multi-drug resistance (1, 2, 3,
4, 5, 6, 7, 8). An antibiotic treatment may take months or years to produce clinical improvement,
especially in patients with an initial high bacterial index (BI).
more
Towards Universal Access to Prevention, Diagnosis and Treatment
O presente Manual realça aspectos desde o diagnóstico e o manuseio dos casos até às medidas a serem tomadas de modo a reduzir a transmissão da tuberculose na
comunidade. Este manual foi desenvolvido para orientar os clínicos e outros profissionais de saúde na gestão dos casos de tuberculose... resistente, desde o nível periférico até ao nível central.
more
The roadmap describes the actions needed to
achieve the three development goals for TB
vaccines set by the WHO:
1. A safe, effective and affordable TB vaccine
for adolescents and adults.
2. An affordable TB vaccine for neonates and
infants with improved safety and efficacy.
3. A therapeutic v...accine to improve TB
treatment outcomes
more
Global Plan to end TB 2016-2020
La presente Nota Informativa sirve como orientación a los solicitantes que están preparando una solicitud de financiamiento del Fondo Mundial para la tuberculosis. Ofrece recomendaciones sobre cómo establecer prioridades y metas para que las intervenciones relacionadas con la tuberculosis consiga...n la máxima repercusión posible. Promueve inversiones estratégicas para salvar vidas y obtener beneficios económicos, teniendo en cuenta la situación de la tuberculosis en cada país y otros factores contextuales:
• Su perfil de tuberculosis: tanto farmacosensible como farmacorresistente.
• El contexto del sistema de salud del país.
• Los obstáculos relacionados con los derechos humanos y el género.
• Las barreras socioeconómicas y estructurales que impiden acceder a los servicios
de tuberculosis.
more
Tuberculosis (TB) control in the African Region has evolved since the disease was declared a global emergency by the World Health Organization (WHO) in 1993. Member States have adopted and implemented successive global and regional strategies and resolutions, with demonstrable positive impacts on in...cidence, prevalence and mortality, albeit with variations across countries. By the end of 2015, the Region as a whole met the key Millennium Development Goal (MDG) target of halting and beginning to reverse TB incidence. However only 35 of the 47 Member States met the MDG target.
more
Washington, D.C., USA, 23-27 September 2018
Provisional Agenda Item 4.6
CD56/10, Rev. 1 31 August 2018
Original: Spanish
In 2019, an estimated 10 million individuals fell ill with tuberculosis (TB) and 3 million of them were not reported to have beendiagnosed and notified. The gap is proportionately even wider for drug-resistant TB. Of the estimated 465 000 patients with rifampicin-resistant and multi-drug resistant T...B (RR/MDR-TB), only 206 030 (44%) were diagnosed and notified.For the first time, the World Health Organization (WHO) has provided global estimates of the incidence of isoniazid resistance: in 2019, there were 1.4 million incident cases of isoniazid-resistant TB, of which 1.1 million were susceptible to rifampicin. Most of these people were not diagnosed with drug-resistant TB and did not receive appropriate treatment.
more